# Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor

> **NCT06556862** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing 302 Hospital** · enrollment: 155 (estimated)

## Conditions studied

- HR+/HER2- Advanced Breast Cancer

## Interventions

- **DRUG:** Dalpiciclib
- **DRUG:** Chidamide
- **DRUG:** Enitinostat

## Key facts

- **NCT ID:** NCT06556862
- **Lead sponsor:** Beijing 302 Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 155 (ESTIMATED)
- **Last updated:** 2025-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06556862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06556862, "Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06556862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*